2018 Competitor Analysis: PRAME-Targeted Immunotherapy - ResearchAndMarkets.com

June 13, 2018

DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Competitor Analysis: PRAME-Targeted Immunotherapy” report has been added to ResearchAndMarkets.com’s offering.

This Competitive Intelligence report analyzes the competitive field of PRAME-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

The report includes a compilation of currently active projects in research and development of passive and active immunotherapy and adoptive cell therapy targeting PRAME. In addition, the report lists company- and institution-specific R&D pipelines of PRAME-Targeted Immunotherapies.

PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors. PRAME was first identified as a tumor-associated antigen through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma.

Subsequently, it has been shown that PRAME is expressed in many malignant neoplasms, including cutaneous melanoma, breast carcinoma, non-small cell lung cancer, and leukemia, whereas normal healthy tissues express minimal or no PRAME, with the exception of the testis and endometrium.

It was shown that PRAME-specific CD8+ T cells isolated from healthy individuals and patients with advanced melanoma were able to recognize and lyse cells expressing HLA class I and high levels of PRAME. Thus, PRAME is a potential candidate for cancer immunotherapy because it is expressed by a variety of tumours and can induce T-cell immune responses.

Competitor projects are listed in a tabular format providing information on:

Drug Codes Target/Mechanism of Action Class of Compound Company Product Category Indication R&D Stage Additional comments with a hyperlink leading to the source of information

Key Topics Covered

1. PRAME-Targeted Immunotherapy

PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines PRAME-Selective Cellular & Recombinant Immunotherapies PRAME-Specific, Multi-Target Adoptive Cell Therapy

2. Corporate & Institutional PRAME Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/n5txrb/2018_competitor?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006278/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/13/2018 06:03 PM/DISC: 06/13/2018 06:03 PM


Update hourly